Quick Takeaways:
- Boehringer Ingelheim announced that the US FDA has approved Vetmedin (pimobendan) for delaying congestive heart failure (CHF) in dogs with Stage B2 preclinical MMVD, making it the only drug approved to treat preclinical heart disease in dogs.
- The approval builds on earlier conditional nod and is backed by studies showing ~15.6 months delay in CHF onset or cardiac death and 79% of dogs remaining CHF-free at 1 year, highlighting strong clinical benefit in early-stage disease.
- With heart disease affecting ~10% of dogs, this expanded indication allows earlier intervention, helping extend symptom-free life, survival, and quality of life in dogs at risk of progression.
Why It Matters?
Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earlier prescribing.
The strong EPIC data (15.6‑month delay, 79% CHF‑free at 1 year) supports premium positioning and durable franchise growth for Boehringer Ingelheim in canine cardiology, while expanding the addressable treated population given MMVD’s high prevalence in dogs.
Source: PRnewswire
